Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04317963 · ClinicalTrials.gov registry record
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 180
- Enrollment target
NCT04317963: Completed study, sponsored by University of Illinois at Chicago.
NCT04317963 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04317963 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
Study Summary
This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical center's specialty outpatient clinic.
Primary Outcome
New episode of C. difficile infection that occurs after initial clinical cure of the baseline episode within 12 weeks of receipt of bezlotoxumab or completion of standard CDI treatment.
Interventions
- BIOLOGICAL Bezlotoxumab
- DRUG Standard CDI treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2023-02-22 |
What the finished NCT04317963 record still lists
NCT04317963 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Bezlotoxumab is the first listed.
NCT04317963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04317963 about?
NCT04317963 is a clinical study titled "Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection". This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical center's specialty outpatient clinic.
What is the current status of trial NCT04317963?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2020-02-12. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT04317963?
The interventions under investigation include: Bezlotoxumab (BIOLOGICAL), Standard CDI treatment (DRUG).
Who is sponsoring clinical trial NCT04317963?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI